Then, many other groups have verified the WIP1 amplification and overexpression in breast cancers [8, 9], neuroblastoma [10], ovarian clear cell carcinoma [11], medulloblastomas [12], colon cancer [13], nasopharyngeal cancer [14], and non-small cell lung cancer (NSCLC) [15]. This evidence concerns the gene PPM1D and non-small cell lung carcinoma.